Holen Sie sich die Stockscreener-App
42.32
5.29%
2.0875
Schlusskurs vom Vortag:
$40.23
Offen:
$40
24-Stunden-Volumen:
5.96M
Relative Volume:
1.95
Marktkapitalisierung:
$3.81B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-95.90M
KGV:
-32.06
EPS:
-1.32
Netto-Cashflow:
$-79.09M
1W Leistung:
+64.24%
1M Leistung:
+129.32%
6M Leistung:
+1,042%
1J Leistung:
+543.71%
1-Tages-Spanne:
$40.00
$45.18
1-Wochen-Bereich:
$25.75
$45.18
52-Wochen-Spanne:
$1.865
$45.18
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
Firmenname
Terns Pharmaceuticals Inc
Sektor
Branche
Telefon
650-525-5535 EXT.101
Adresse
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Vergleichen Sie TERN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TERN
Terns Pharmaceuticals Inc
|
42.34 | 3.62B | 0 | -95.90M | -79.09M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.97 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.88 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
892.65 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.75 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-11-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-04 | Fortgesetzt | H.C. Wainwright | Neutral |
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2024-10-31 | Eingeleitet | Oppenheimer | Outperform |
| 2023-06-22 | Eingeleitet | Mizuho | Buy |
| 2023-06-07 | Eingeleitet | Jefferies | Buy |
| 2023-05-31 | Eingeleitet | ROTH MKM | Buy |
| 2023-05-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-02-14 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-02-07 | Eingeleitet | UBS | Buy |
| 2022-09-12 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-09-14 | Fortgesetzt | Goldman | Buy |
| 2021-03-02 | Eingeleitet | Cowen | Outperform |
| 2021-03-02 | Eingeleitet | Goldman | Buy |
| 2021-03-02 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Terns Pharmaceuticals Inc Aktie (TERN) Neueste Nachrichten
Terns Pharmaceuticals: CML Data Blows Wall Street AwayAgain (NASDAQ:TERN) - Seeking Alpha
Terns Pharmaceuticals Stock Skyrockets: Should You Dive In? - StocksToTrade
Terns (TERN) Hits All-Time High on Stellar Leukemia Treatment Results - Insider Monkey
Oppenheimer Raises TERN Price Target by 107% to $58 | TERN Stock News - GuruFocus
Terns Pharma (TERN) Analyst Rating Update: Price Target Raised b - GuruFocus
Barclays Raises Terns Pharma (TERN) Price Target to $56 | TERN Stock News - GuruFocus
Terns Pharmaceuticals price target raised to $56 from $35 at Truist - TipRanks
Terns Pharmaceuticals (TERN) Announces $400M Public Offering Pla - GuruFocus
Mizuho Raises Terns Pharma (TERN) Price Target to $54, Maintains Outperform Rating | TERN Stock News - GuruFocus
Oppenheimer Adjusts PT on Terns Pharmaceuticals to $58 From $28, Maintains Outperform Rating - marketscreener.com
Broadcom To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Terns Pharmaceuticals price target raised to $58 from $28 at Oppenheimer - TipRanks
Terns Pharmaceuticals price target raised to $54 from $33 at Mizuho - TipRanks
Truist Raises Price Target on Terns Pharmaceuticals to $56 From $35, Keeps Buy Rating - marketscreener.com
Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster - Benzinga
H.C. Wainwright raises Terns Pharmaceuticals stock price target to $60 on CML drug data - Investing.com UK
Mizuho raises Terns Pharmaceuticals stock price target to $54 on CML drug data - Investing.com
Terns Pharmaceuticals (TERN) Launches $400M Public Offering - GuruFocus
Terns Pharmaceuticals proposes $400M equity offering - MSN
Terns Pharmaceuticals (TERN) Launches $400M Public Stock Offerin - GuruFocus
Terns Pharmaceuticals Launches $400 Million Public Offering - Nasdaq
Terns Announces Proposed Public Offering - The Manila Times
Terns announces proposed public offering - marketscreener.com
Terns Pharmaceuticals launches $400 million public offering By Investing.com - Investing.com India
Terns Pharmaceuticals (Nasdaq: TERN) starts $400M stock offering with $60M option - Stock Titan
Terns Pharmaceuticals stock rating reiterated by BMO Capital with $54 target - Investing.com India
Terns Pharmaceuticals Stock Soars After Leukemia Drug Delivers Big Early Responses In Tough-To-Treat Patients - Stocktwits
Terns Pharmaceuticals (TERN): Evaluating Rich Valuation After CARDINAL Trial Update and 2025 ASH Presentation - simplywall.st
10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs - Insider Monkey
Terns CEO says 'delighted' by 'unprecedented' Phase 1 data for TERN-701 - MSN
Oppenheimer raises Terns Pharmaceuticals stock price target to $58 on CML drug data - Investing.com Canada
Terns Pharmaceuticals’ Path: A Stock to Watch? - timothysykes.com
Terns Pharmaceuticals Unveils Promising Phase 1 Trial Data - TipRanks
Terns Pharmaceuticals Presents Positive Phase 1 Data for TERN-701 in CML - TradingView
Terns Pharmaceuticals says safety profile maintained with longer treatment duration - marketscreener.com
Terns’ leukemia drug shows 64% response rate in phase 1 trial - Investing.com
Terns Pharmaceuticals (TERN) Unveils Promising Data from CARDINA - GuruFocus
Terns Pharmaceuticals stock soars after positive Phase 1 CML drug data By Investing.com - Investing.com South Africa
Terns Pharmaceuticals stock soars after positive Phase 1 CML drug data - Investing.com UK
Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701’s Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting - The Manila Times
Terns drug shows potential to challenge Novartis’ blockbuster leukemia treatment - BioPharma Dive
Results in Terns leukemia drug study suggest it could be a successor to Novartis blockbuster - statnews.com
Terns (Nasdaq: TERN) posts 80% MMR, 36% DMR in Phase 1 TERN-701 CML data at ASH 2025 - Stock Titan
Why Terns Pharmaceuticals Shares Are Under Pressure - TipRanks
Terns Pharmaceuticals unveils promising phase 1 trial data - MSN
Terns Pharmaceuticals (TERN) Price Target Increased by 16.10% to 31.05 - Nasdaq
Terns Pharmaceuticals stock hits all-time high at 29.53 USD By Investing.com - Investing.com Nigeria
Terns Pharmaceuticals stock hits all-time high at 29.53 USD - Investing.com
Can Terns Pharmaceuticals Inc. stock deliver consistent earnings growthWeekly Gains Summary & Technical Analysis for Trade Confirmation - Newser
Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors - Yahoo Finance
Why Terns Pharmaceuticals Inc. stock could rally in 2025Weekly Investment Recap & Step-by-Step Swing Trade Plans - Newser
Finanzdaten der Terns Pharmaceuticals Inc-Aktie (TERN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):